- Numinus Wellness stocks have rocketed over 373 per cent in the last one month. The size of its stock has been doubled since its listing on the Toronto Stock Exchange Venture (TSXV) in June this.
- The healthcare stock made it to TMX’s top healthcare, top volume, and Rising Stars list.
- The company raised CS$ 10 million from its latest offering on December 7.
Healthcare companies are constantly trending in the stock markets these days on the back of innovative therapies research and development. Numinus Wellness Inc. (TSXV) and the Multidisciplinary Association for Psychedelic Studies Public Benefit Corp. (MAPS PBC), a MAPS (non-profit research and educational organization) affiliate, announced that they are pursuing a permit for the use of 3,4-Methylenedioxymethamphetamine (MDMA)-supported psychotherapy for post-traumatic stress disorder testing in Canada. The announcement was made in the first week of December.
Let us have a quick look at Numinus’ stock performance:
Numinus Wellness Inc. (TSXV: NUMI)
Current Stock Price: C$ 2.06
Stocks of healthcare firm Numinus Wellness, which therapies and corresponding research and development, have zoomed over 373 per cent in the last one month. The stock has returned exactly 100 per cent of growth since its listing in June this year.
The healthcare service provider has been ranked among TMX’s top healthcare stocks across TSXV and TSX that has outperformed their peers in the last 30 days. The company also made it to TMX’s Rising Stars stock list that has TSXV-listed stocks with the largest price gains in the last 3 months. The company is placed among TMX’s Top Volume stocks that have traded most actively in the last 10 days.
Its 10-day average stock trading volume is 4.62 million units. Its current market cap stands at approximately C$ 236 million. Its current debt to equity ratio is 0.08, as per TMX data.
Numinus Wellness One-Month TSX Chart (Source: Refinitiv, Thomson Reuters)
Canaccord Genuity Corp. and Eight Capital have agreed to buy an aggregate of 14,706,000 units of Numinus Wellness at a price of C$ 0.68 per stock for an aggregate gross of nearly C$ 10 million offering on December 7.
Numinus become the first public listed company that received Health Canada-issued Controlled Drugs and Substances Dealer's License for its Psilocybe mushrooms facility.